Mortality associated with tuberculosis/HIV co-infection among patients on TB treatment in the Limpopo province, South Africa.

Tiyani. E Mabunda¹, Nalezani J Ramalivhana ², Yoswa M Dambisya³

1. Limpopo Provincial Department of Health, Polokwane 0700; South Africa
2. Department of Public Health, University of Limpopo, Sovenga 0727, South Africa.
3. Department of Pharmacy, University of Limpopo, Sovenga 0727, South Africa.

Abstract

Background: South Africa has a high tuberculosis burden, and Limpopo Province experienced higher than national average TB mortality rates between 1997 and 2008.

Objective: To establish factors associated with TB mortality in Limpopo Province in 2008.


Results: In 2008, some 18074 patients started treatment: 15995 (88.5%) had pulmonary TB (PTB), while 2079 (11.5%) had extrapulmonary TB (EPTB). Overall, 2242 (12.4%) patients died, mainly PTB patients (n=1906; 85%), more males (n=1159; 51.7%), mainly those aged 25 to 54 years (n=1749, 78.0%), and new cases (1914; 85.4%). TB mortality was significantly higher among smear negative than smear positive patients (17% vs 13.8%; P<0.001), among those with EPTB compared to PTB patients (P<0.001), and among re-treatment cases (P<0.001). Only 4237 (23.4%) patients had HIV status known, with higher mortality found among HIV positive than the HIV negative patients (P<0.0001); but HIV status was not known for the majority who died (n=1685, 75.2%).

Conclusion: Higher mortality was associated with age 22-55 years; smear negativity, EPTB, HIV infection, and re-treatment. The findings call for greater integration of TB control efforts and HIV services, especially among the 22-55 year age group.

Keywords: Tuberculosis/HIV, Limpopo, South Africa

DOI: http://dx.doi.org/10.4314/ahs.v14i4.12

Introduction

South Africa was ranked fifth among the 22 tuberculosis (TB) high burden countries in 2007 and third after India and China among the 22 countries carrying 82% of global TB burden in 2010. According to the World Health Organization (WHO) Global TB Report 2009, South Africa had nearly 460 000 new TB cases in 2007 with an incidence rate of 948 cases per 100 000 population, and a TB prevalence rate of 692 per 100 000 population per year. South Africa has the largest number of people living with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS), as a result HIV associated TB has become a major clinical and public health problem.

The (HIV) epidemic that has progressed in tandem with TB infection poses a big threat to TB Control effort.

Limpopo is one of the poorest provinces of South Africa, with relatively poor infrastructure and public services, including health. The province has a vibrant TB Control Programme that works according to the national guidelines, including the capture of TB statistics on the electronic database, ETR.Net. Programmatic data shows that the recorded number of TB cases in the Limpopo Province increased more than threefold from 6286 in 2000 to 22836 in 2009. However, the bacteriological coverage decreased from 90.7% to 79.9% over the same period. At the same time, the death rate in new smear positive patients in the province was consistently higher than the national average between 1997 and 2008.

The Desmond Tutu TB Centre, University of Stellenbosch, in collaboration with the National Department of Health, is coordinating efforts to strengthen the capacity of the provinces to conduct operations re-
search on TB. In this context, the Limpopo Province team undertook a study on the high death rates among TB patients on treatment, with a view to contribute to understanding the factors responsible for the high TB mortality rate in the province. “Died” was taken to refer to a TB client who died from any cause during treatment, according to WHO guidelines. The aim of the study was to assess the factors associated with mortality among TB patients who started treatment between 01 January and 31 December 2008.

Study design

Methodology

This was a quantitative, retrospective study using ETR.Net provincial data for patients who initiated TB treatment from 1 January 2008 to 31 December 2008. The data were imported from ETR.net to Microsoft Excel, using a data capture template that was developed for that purpose. The data were then analysed to establish the TB mortality for the year, and the characteristics of patients who died.

Study population

All TB patients who died after starting treatment from 1 January until 31 December 2008 were included in the study.

Data collection

The age and sex of patients that died after commencement of treatment in 2008 were recorded. The association between smear positivity and outcome were analysed using a 2X2 table matching smear positivity and outcome. Where the diagnosis was confirmed, it was noted as after smear test and post hoe Bonferroni’s correction, with P< 0.05 as the limit of significance.

Results

A total of 18074 patients (52.3% male) started treatment during the year 2008. Of those 15995 (88.5%) had pulmonary TB, while 2079 (11.5%) had extra pulmonary TB; 16013 (88.6%) were new cases, 964 (5.3%) were relapses, 622 (3.4%) had previously defaulted, 288 (1.6%) had a history of treatment failure, and 187 (1.0%) were “all other retreatment” cases. The number of deaths recorded for the period under review was 2242 (12.4%), being 1083 (48.3%) female and 1159 (51.7%) male, with no gender-related difference in TB mortality.

Proportionately, 12% of the new cases died compared to 15.1% of the relapse cases, 16.7% of those with a history of defaulting, 15.6% of those with history of treatment failure, and 16.6% of those categorised as “others”. The likelihood of death was significantly higher among retreatment cases than among the new cases (X2 = 21.8; df = 1; P<0.001). Regarding treatment regimens, most of the patients (79.3%) were on Regimen 1 (2RHZE + 4HR; N=1777); while 323 (14.4%) were on Regimen 2 (2RHZES + 1 RHZE + 5HRE); 108 (4.8%) were on Regimen 3 (paediatric 2RHZ + 4HR); and 34 (1.5%) were on others treatment, including chemotherapy. There was a significant association between treatment regimen and TB mortality: those on Regimen 2 (re-treatment) were more likely to die than were new cases on Regimen 1 (17.2% vs 11.1%; X2 = 45.7; df=1; P<0.001).

New cases accounted for 85.4% (n=1914) of total mortality, while 146 (6.5%) deaths were relapsed PTB cases, 104 (4.6%) were those who had previously defaulted treatment; 45 (2.0%) had history of treatment failure; and 31 (1.4%) were other retreatment cases. Proportionately, 12% of the new cases died compared to 15.1% of the relapse cases, 16.7% of those with a history of defaulting, 15.6% of those with history of treatment failure, and 16.6% of those categorised as “others”. The likelihood of death was significantly higher among retreatment cases than among the new cases (X2 = 21.8; df = 1; P<0.001). Regarding treatment regimens, most of the patients (79.3%) were on Regimen 1 (2RHZE + 4HR; N=1777); while 323 (14.4%) were on Regimen 2 (2RHZES + 1 RHZE + 5HRE); 108 (4.8%) were on Regimen 3 (paediatric 2RHZ + 4HR); and 34 (1.5%) were on others treatment, including chemotherapy. There was a significant association between treatment regimen and TB mortality: those on Regimen 2 (re-treatment) were more likely to die than were new cases on Regimen 1 (17.2% vs 11.1%; X2 = 45.7; df=1; P<0.001).

Figure 1: Age Range (Years) Distribution of Patients who died in 2008

Figure 2: TB mortality within the age groups increased with age, with the groups 24 years and below recording the least 10% mortality rate (8.4 among those aged 4 years and below, 4.7% among those aged 5 to 14 years, and 5.5% among the 15-24 year group); while those aged 25 years and above had mortality rates higher than 10% (13.8% among the 25 to 54 years, 15.7% among the 55 to 74 year group, and 23.3% among those older than 75 years.

Statistical analysis

Summary statistics were generated using Microsoft Excel, while SPSS version 20 was used for further analysis of the data for association between various variables and TB mortality. The association between variables and mortality was tested using the Chi-square test and post hoc Bonferroni’s correction, with P< 0.05 as the limit of significance.

Ethical considerations

The study protocol was approved by the University of Limpopo Polokwane-Mankweng Research Ethics Committee. In addition, permission was obtained from the Limpopo Province Department of Health and Social Development Research Committee, and the proposal was further reviewed and approved by the International Union against TB and Lung Diseases (IUATLD) prior to commencement of the study. This was a non-intrusive study that utilized retrospective data. All data captured were without specific patient identifiers, to ensure the anonymity of the patients, and all the information obtained was treated with utmost confidentiality.
The association between HIV infection and TB mortality was evident in the present study: HIV positive patients were more likely to have EPTB and more likely to be smear negative, and mortality was higher among those who were HIV positive. Unfortunately, HIV counselling and testing (HCT) was done in less than a quarter of the patients that started treatment that year, hence the full impact of HIV infection on TB mortality in this setting HIV integrated services, it is apparent from the findings here in presented that HCT and/or uptake of HIV testing for TB patients may not have been as widespread as envisaged by established guidelines. Higher TB mortality among those who are HIV infected has been reported by others. The low levels of HIV testing in TB patients means that many of those who may benefit from HAART are missed out, and yet HAART has been shown to improve treatment outcomes in HIV infected persons with TB. Moreover, as suggested by Nahed et al, TB patients with HIV infection may require longer than standard therapy to avoid relapse or treatment failure. Clearly, in order for those who are TB-HIV co-infected to benefit from interventions such as co-trimoxazole preventive therapy (CPT) and HAART as advocated by WHO, there must be HIV testing among all TB patients and intensified case-finding for TB among people living with HIV. Efforts in this regard need to be strengthened in the Limpopo Programme in order for the province to meet the global targets of all TB patients tested for HIV, and all TB patients living with HIV provided with anti-retroviral therapy, and isoniazid preventive therapy for HIV positive people without active TB.

There were more males among those that died, which is explicable from the larger number of males among the recorded patients for the year under review. Similarly, the highest number of TB patients recorded was in the age group 25-54 years, and so were the majority of those who died. This age group is the most economically active population, so such high morbidity and mortality has to be addressed to mitigate the possible negative impact on human development. The 25-54 year age group is also the one most affected by HIV infection, and it is likely that TB-HIV co-infection is partly responsible for both the high morbidity and mortality in that age group. The preponderance of new cases in the province, and among those who died, suggests measures to curb TB transmission were not effective, and that the population was not sensitized to seek treatment early.

Patients that were on retreatment had higher mortality than the new cases, which is consistent with findings from Kwa-Zulu Natal. Indeed the retreatment regimen remains of questionable efficacy. The programmatic implication of this finding is that strategies such as DOTS should be promoted and adherence enforced to avoid default and treatment failure which necessitate retreatment with less effective regimens.

The lack of data on smear grading and culture and sensitivity, the high number of PTB cases with no smear results (32.4%), and the low rate of HIV testing were limitations of the study. The lack of microbiological data is not unique to the Limpopo TB Control Programme, similar observations have been made by others; indeed, Komati et al view this as an African wide problem. Impediments to HIV integrated services, it is apparent from the findings here in presented that HCT and/or uptake of HIV testing for TB patients may not have been as widespread as envisaged by established guidelines. Higher TB mortality among those who are HIV infected has been reported by others. The low levels of HIV testing in TB patients means that many of those who may benefit from HAART are missed out, and yet HAART has been shown to improve treatment outcomes in HIV infected persons with TB. Moreover, as suggested by Nahed et al, TB patients with HIV infection may require longer than standard therapy to avoid relapse or treatment failure. Clearly, in order for those who are TB-HIV co-infected to benefit from interventions such as co-trimoxazole preventive therapy (CPT) and HAART as advocated by WHO, there must be HIV testing among all TB patients and intensified case-finding for TB among people living with HIV. Efforts in this regard need to be strengthened in the Limpopo Programme in order for the province to meet the global targets of all TB patients tested for HIV, and all TB patients living with HIV provided with anti-retroviral therapy, and isoniazid preventive therapy for HIV positive people without active TB.

There were more males among those that died, which is explicable from the larger number of males among the recorded patients for the year under review. Similarly, the highest number of TB patients recorded was in the age group 25-54 years, and so were the majority of those who died. This age group is the most economically active population, so such high morbidity and mortality has to be addressed to mitigate the possible negative impact on human development. The 25-54 year age group is also the one most affected by HIV infection, and it is likely that TB-HIV co-infection is partly responsible for both the high morbidity and mortality in that age group. The preponderance of new cases in the province, and among those who died, suggests measures to curb TB transmission were not effective, and that the population was not sensitized to seek treatment early.
Acknowledgements: The study was supported by USAID through the Desmond Tutu TB Centre, University of Stellenbosch coordinated Operations Research Assistance Project (ORAP). We thank Mr MM Gafar for his assistance in data collection, and the anonymous AHS reviewers for their helpful comments.

References